Loading stock data…
$211.13+0.77 (+0.37%)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Jazz Pharmaceuticals plc in the Healthcare sector is trading at $210.39 with a market capitalization of $15.6B. Wall Street consensus targets $294.64 (22 analysts), implying a +40.0% move over the next 12 months. The stock is currently 21% below its 52-week high of $266.38, remaining 1.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.21B↑ | $1.07B↓ | $1.20B↑ | $1.13B↑ | $1.05B |
| Gross Profit | $1.09B↑ | $934.80M↓ | $1.04B↑ | $997.23M↑ | $929.40M |
| Operating Income | $325.20M↓ | $336.60M↑ | $254.53M↑ | $100.01M↓ | $219.00M |
| Net Income | $192.80M↓ | $293.10M↑ | $203.45M↓ | $251.41M↑ | -$718.50M |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...